MX337566B - Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. - Google Patents

Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.

Info

Publication number
MX337566B
MX337566B MX2012007797A MX2012007797A MX337566B MX 337566 B MX337566 B MX 337566B MX 2012007797 A MX2012007797 A MX 2012007797A MX 2012007797 A MX2012007797 A MX 2012007797A MX 337566 B MX337566 B MX 337566B
Authority
MX
Mexico
Prior art keywords
artemisinin
derivative
combination
treating cancer
immunomodulatory compound
Prior art date
Application number
MX2012007797A
Other languages
English (en)
Other versions
MX2012007797A (es
Inventor
Angus Dalgleish
Andrew Gravett
Wai Liu
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2012007797A publication Critical patent/MX2012007797A/es
Publication of MX337566B publication Critical patent/MX337566B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan los métodos para tratar cánceres mediante la administración de compuestos inmunomoduladores en combinación con artenisinina o un derivado de ésta. En particular se proporcionan los métodos para tratar cánceres mediante la administración de compuestos inmunomoduladores en combinación con lenalidomida en combinación con artenisinina o un derivado de ésta.
MX2012007797A 2010-01-05 2011-01-05 Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. MX337566B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29230710P 2010-01-05 2010-01-05
US37134710P 2010-08-06 2010-08-06
PCT/US2011/020160 WO2011084968A1 (en) 2010-01-05 2011-01-05 A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer

Publications (2)

Publication Number Publication Date
MX2012007797A MX2012007797A (es) 2012-08-23
MX337566B true MX337566B (es) 2016-03-10

Family

ID=43533145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007797A MX337566B (es) 2010-01-05 2011-01-05 Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.

Country Status (5)

Country Link
US (1) US9226913B2 (es)
EP (2) EP2851070A1 (es)
CA (1) CA2786266A1 (es)
MX (1) MX337566B (es)
WO (1) WO2011084968A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314460B1 (en) * 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
US9918972B2 (en) * 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
CN109675048B (zh) * 2019-01-07 2020-12-15 中国科学院化学研究所 一种抗癌前药脂质体及青蒿素类脂质体纳米药物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101502T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
EP1095043A1 (en) 1998-07-14 2001-05-02 The Hong Kong University of Science & Technology Trioxane derivatives
CN1342146A (zh) 1999-03-18 2002-03-27 塞尔基因公司 取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
NZ555886A (en) 2004-12-01 2009-12-24 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
EP1848433A2 (en) 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
EP2289554A1 (en) * 2009-07-31 2011-03-02 Dafra Pharma N.V. Compositions comprising thalidomide and artemisinin for the treatment of cancer

Also Published As

Publication number Publication date
US9226913B2 (en) 2016-01-05
CA2786266A1 (en) 2011-07-14
US20130136757A1 (en) 2013-05-30
MX2012007797A (es) 2012-08-23
EP2851070A1 (en) 2015-03-25
EP2521543B1 (en) 2016-04-13
EP2521543A1 (en) 2012-11-14
WO2011084968A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
EP2542585B8 (en) Methods for treating colorectal cancer
PH12012502194A1 (en) Indoles
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
PH12016502066A1 (en) Methods of treating bladder cancer
EP2542583B8 (en) Methods for treating breast cancer
WO2014018563A3 (en) Methods for the treatment of cancer
AU2012335543A8 (en) HER3 antibodies and uses thereof
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
MX342709B (es) Tratamiento contra el cancer.
MX2012012118A (es) Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
SG10201500124VA (en) Methods and Compositions for Treating Cancer
PH12015501088A1 (en) Dimeric compounds
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
MX2012007797A (es) Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
WO2013025939A9 (en) Compounds and methods for treating cancer by inhibiting the urokinase receptor
IL225520A0 (en) History of 4-(methylaminophenoxy)pyridin-3-yl-benzamide for cancer treatment
EP2663318A1 (en) Pharmaceutical composition for treating cancer
MX350868B (es) Medicamentos y metodos para tratar cancer.
EA201070295A1 (ru) Лечение рака легких
HK1196780A (en) Combination therapy for ovarian cancer
HK1191599A (en) Compositions and methods for treating cancer
AU2012901918A0 (en) Methods for treating cancer
SG10201601715YA (en) Novel Pharmaceutical Combinations And Methods For Treating Cancer

Legal Events

Date Code Title Description
FG Grant or registration